 Aditxt Inc NASDAQ: ADTX has announced data from Phase 3 PRESECO trial evaluating oral AviganReeqonus favipiravir as a potential at-home therapy for mild-to-moderate COVID-19, run by Appili Therapeutics Inc. The trial did not achieve statistical significance on the primary endpoint of time to sustained clinical recovery. Additional analyses of the trial data are ongoing. 